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Abstract
We postulated that changes in the cell surface display of 
molecules that facilitate cell-cell and cell-matrix adhesions 
may reflect the changing immunosurveillance capacity of 
blood monocytes during progression of human immunode­
ficiency virus (HIV) infections. In Centers for Disease Con­
trol (CDC) stage A patients, whose monocytes’ ability to 
phagocytose bacteria and generate reactive oxygen interme­
diates is often increased, the frequency of monocytes ex­
pressing CD49d, HLA-DP, HLA-DQ, and an activation epi­
tope of CDlla/CD18 was increased and monocyte transen- 
dothelial migration was unimpaired, In CDC stage B/C 
patients, whose monocytes’ ability to phagocytose bacteria 
and migrate across confluent endothelial monolayers was 
diminished, surface expression of CD49e and CD62L and 
the percentage of monocytes expressing CD18, CDlla, 
CD29, CD49e, CD54, CD58, CD31, and HLA-I were signifi­
cantly decreased. Incubating normal donor monocytes with 
immune complexes in Yitro reproduced the phenotypic and 
functional abnormalities seen in stage B/C patients. By con­
trast, in vitro stimulation with subcellular particulates re­
leased by apoptotic lymphocytes reproduced changes seen 
in stage A patients* monocytes. Although circulating mono­
cytes appear to be activated at all stages, these data suggest 
that the high levels of circulating immune complexes, found 
predominantly in the later stages of HIV infection, may be 
particularly instrumental in reducing the monocyte’s capac­
ity to maintain surveillance against infection, (ƒ. Clin. Invest 
1995. 95:1690-1701.) Key words: HIV • monocyte • phago­
cytosis • antigen-antibody complex • apoptosis
Introduction
After the onset of human immunodeficiency virus (HIV) infec­
tion there is often a latent period during which infected individu­
als remain asymptomatic even though the virus continues to
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replicate in lymphoid tissues (1, 2 ). During this interval, when 
patients have not yet experienced significant bacterial or fungal 
infections, the ability of their circulating monocytes and pulmo­
nary alveolar macrophages to phagocytose microorganisms, 
generate reactive oxygen intermediates (ROIs),1 and kill in­
gested bacteria remains within normal limits and in some cases 
may be greater than in normal controls (3, 4). Even direct HIV 
infection of monocytes in vitro does not immediately impair 
the ability of these cells to phagocytose bacteria, generate ROIs, 
and kill opsonized Escherichia coli or Candida albicans (5), 
although with prolonged culture, infected monocytes can be­
come dysfunctional (6). Retention of monocyte antibacterial 
activity, early in HIV-1 infection, is consistent with the observa­
tion that infection with this virus causes monocytoid cells to 
differentiate and display molecules that actually facilitate cell­
cell adhesive interactions (7, 8).
Eventually, critical monocyte functions decline in vivo (9, 
10), and their ability to respond to-chemotactic stimuli (11), 
phagocytose bacteria ( 12), and clear opsonized particles from 
the circulation (13) may become impaired, although their ability 
to phagocytose and kill Cryptococcus neoformans, Aspergil­
lus fumigatus, and other fungi may remain intact for some 
time (14).
To identify the molecular basis for the apparent decline 
in monocyte/macrophage function during the course of HIV 
infection, we have studied the cell surface phenotypes, phago­
cytic activity, reactive oxygen production, and transendothelial 
migratory capacity of peripheral blood monocytes from asymp­
tomatic HIV-infected patients and patients who have experi­
enced one or more serious infections, under the hypothesis that 
changes in the expression of specific cell surface molecules may 
play a role in the development of the observed functional de­
fects. By means of in vitro studies, we have attempted to model 
the changes observed in vivo and have identified factors that 
are likely to cause the observed abnormalities.
Methods
Experimental subjects. 74 patients were recruited from the outpatient 
clinic for HIV-infected individuals at the VA Medical Center, Houston, 
TX, under a protocol approved by the institutional review board and
1. Abbreviations used in this paper: CDC, Centers for Disease Control; 
CH50, estimate of total hemolytic complement activity; DCFDA, dihy- 
drochlorofluorescein diacetate (C400); MCF, mean channel fluores­
cence; MNL, mononuclear leukocyte; NK, natural killer; PE, phycoer- 
ythrin; ROI, reactive oxygen intermediate.
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staged according to current criteria of the Centers for Disease Control 
(CDC) (15). None had or had had an opportunistic infection within 
the 4-wk period before these studies. Healthy men were recruited from 
laboratory and hospital personnel. Venous blood was collected in poly­
propylene syringes, using preservative-free, pharmaceutical grade hepa­
rin (Squibb-Marsam, Inc., Cherry Hill, NJ). Blood was also collected 
without anticoagulant and with EDTA to provide serum and plasma, 
respectively. These were stored at — 70°C until tested.
Because of the time required and quantities of blood needed for each 
of the several assays, it was not possible to perform all measurements on 
the same blood sample in a single day. Therefore, distinct groups of 
patients were recruited to study monocyte cell surface phenotype, phago­
cytic function and ROI production, and transendothelial migration. Sam­
ples from one or more healthy control donors were tested concurrently 
with each patient sample, using identical reagents under identical condi­
tions. Monocyte cell surface phenotypes were evaluated in 25 patients, 
using a comprehensive panel of mAbs. Next, we examined the relation­
ship between cell surface molecules shown to be abnormally displayed 
on monocytes of HIV-infected subjects (summarized in Table II) and 
the capacity of monocytes to phagocytose bacteria and generate ROIs. 
Monocyte phagocytosis and ROI production were studied in 23 patients; 
methods developed for these evaluations and the results of studies in 
the 13 patients classified as CDC stage A have been previously reported
(3); the results obtained in the 10 patients classified as CDC stage B/C 
are reported here. Finally, we measured mononuclear leukocyte (MNL) 
migration across endothelial monolayers with blood from 26 patients, 
The methods developed to investigate this behavior and the results of 
tests on blood from 17 stage A patients have previously been reported 
(15). Additional studies of the effects of HIV infection on the ability 
of lymphocytes to migrate across confluent endothelium will be reported 
separately (Birdsall, H. HM J. Trial, A. L. de Jong, L. K. Green, A. H. 
Laughter, and R. D, Rossen, manuscript submitted for publication.)
Reagents. mAbs (clone numbers in parentheses) against CDs 31 
(clone 5.6E), 32 (clone 2E1), 34 (clone QBEND 10), 36 (clone 
FA6.152), 41a (clone P2), 44 (clone J173), 49e (clone SAM 1), 49f 
(clone GoH3), 57 (clone NCI), 58 (clone AICD58), 61 (clone SZ 
21), and 71 (clone YDJ1.22) were obtained from Amac, Inc. (West­
brook, ME). A hybridoma producing a mAb against an MHC class I 
framework antigen (clone BB7.5) was obtained from the American 
Type Culture Collection (Rockville, MD). Antibodies against CDs 4 
(Leu-3a + 3b) (clones SK3, SK4), 11c (clone SHCL-3), 15 (clone 
M M A), 16 (clone G022), 19 (clone 4G7), 33 (clone P67.6), 35 (clone 
44D ), and 45 (clone 2D1), HLA-DP (clone B7/21), HLA-DQ (clone 
SK10), and HLA-DR (clone L243), as well as T cell receptors (TCRs) 
a t¡5 (clone WT31) and y/<5 (clone 11F2), were obtained from Becton 
Dickinson (San Jose, CA). Phycoerythrin (PE)-conjugated mAbs 
against CD14 (clone 116) and unconjugated mAbs against CDs lib  
(clone 94) and 56 (clone 3B8) were obtained from Coulter Immunology 
(Hialeah, FL). NKI-LI6, a mAb against the activated form of CD1 la, 
was prepared and characterized as previously described (16). Anti- 
CD64 (clone 32.2) was obtained from Medarex, Inc. (West Lebanon, 
NH). Anti-CD29 (clone 18D3) and anti-CD49d (clone 20E4) were 
gifts from Dr. B. W. McIntyre (M. D. Anderson Cancer Center, Hous­
ton, TX). Antibody 20E4 is directed against a different epitope of 
CD49d than L25, a standard anti-CD49d (17). Antibodies against 
C D lla  (clone R3.1), CD18 (clone R15.7), and CD54 (clone RR1 / 
1) (18) were gifts from Dr. Robert Rothlein (Boehringer-Ingelheiin 
Pharmaceuticals, Inc., Ridgefield, CT). Anti-CD62L (L-selectin) (clone 
DREG56) (19) was a gift of Dr. Wayne Smith (Baylor College of 
Medicine, Houston, TX). Antibodies against CD49b (clone PIE 6) and 
CD49c (clone P1B 5) were obtained from Telios Pharmaceuticals, Inc. 
(San Diego, CA). A mAb to the CD4 domain of HIV-1 gpl20 (clone 
1536) that reacts with the site in gpl20 that binds to CD4 (20) was a 
gift from Dr. Michael Fung (Tanox Biosystems, Houston, T X ). Isotype 
controls were obtained from Coulter Immunology except for IgG3, 
which was from Zymed Laboratories, Inc. (South San Francisco, CA). 
A single lot of mAbs was used for each antigen in tests of both patients 
and controls. The secondary antibody was FITC-conjugated F(ab')2
affinity-purified sheep anti-mouse Ig (not cross-reactive with human 
Ig) from Cappel (Organon Teknika Corp., West Chester, PA).
Zymosan, LPS from E. coli serotype 0127:B8, and purified human 
IgG were obtained from Sigma Chemical Co. (St. Louis, MO). IgG 
was aggregated at a concentration of 2 mg/ml in veronal-buffered saline, 
pH 7.4, at 63°C for 20 min. E. coli strain HB101 was obtained from 
Dr. Michael McShan and Streptococcus pneumoniae strain 14 was from 
Dr. David Watson (both at the VA Medical Center, Houston, TX), 
Recombinant cytokines were obtained from Genzyme Corp. (Boston, 
MA). Recombinant HIV-1 proteins, gpl20, gpl60, rev, nef, tat, p24, 
and reverse transcriptase were obtained from American Bio-Technolo­
gies, Inc. (Cambridge, MA),
Immunofluorescence studies of blood leukocytes. Heparinized blood 
was distributed in 0.1-ml aliquots into polypropylene tubes for incuba­
tion with saturating concentrations of primary or secondary antibodies 
at 4°C for 30 min. Incubations were separated by two washes with ice- 
cold Dulbecco’s PBS (Gibco Laboratories, Grand Island, NY). FITC- 
conjugated sheep anti-mouse Ig was used at a dilution of 1:120. PE- 
conjugated anti-CD 14, added after the secondary antibody, was used 
according to the manufacturer’s directions. After leukocytes were 
stained and washed, red cells were lysed with FACS Lysing Solution 
(Becton Dickinson). Leukocytes were washed again, fixed in 1% para­
formaldehyde, and analyzed by flow cytometry the day of the experi­
ment. Leukocytes routinely lacked adherent activated platelets, as shown 
by testing with mAb to GMP-140 (CD62, Immunotech, Marseilles, 
France), Total white blood cell (Coulter Counter, Coulter Electronics, 
Hialeah, FL) and differential counts were measured in aliquots of the 
same blood samples used for immunofluorescence studies. Tests of 
control blood donors were randomly interspersed among patient sam­
ples.
Flow cytometry was performed on an Epics Profile I (Coulter Cy­
tometry, Hialeah, FL) with an argon laser tuned to 488 nm and with three 
fluorescence channels. Daily alignment and calibration of the instrument 
were done with DNA-check and Standard-Brite fluorescent beads 
(Coulter Corp.). Green (FL1), orange (FL2), and red (FL3) fluores­
cence signals were measured on a four-decade logarithmic scale. Linear­
ity of log fluorescence intensity was checked with Immuno-Brite fluo­
rescent beads, FL1 was compensated for spectral overlap by 6% of 
the FL2 signal. FL2 was compensated by 19% of FL1, and FL3 was 
compensated by 10% of FL1 and 35% of FL2. The mean intensity of 
fluorescence, which is measured on a four-decade logarithmic scale, 
was converted to a linear scale, using a 256-channel histogram, to give 
a mean channel number, also known as mean channel fluorescence 
(MCF), that is, the estimate of the average fluorescence emission of 
the cells reactive with a specific mAb.
Leukocytes were initially selected for fluorescence analysis by a 
combination of right-angle and low-angle forward light scatter proper­
ties. Two-color fluorescence, with PE-conjugated anti-CD 14 as a quali­
fier, was used to identify specifically monocytes. At least 2,500 mono­
cytes were analyzed in each sample. Fluorescence data from isotype 
controls were subtracted from data obtained with all reported antibodies.
Phagocytosis and oxidative burst. Staphylococcus aureus strain 
25923 from the American Type Culture Collection was stained with 
Texas Red (Molecular Probes, Eugene, OR) and used in a previously 
described flow cytometric assay to enumerate monocytes capable of 
phagocytosing bacteria (3). ROI production was also measured by flow 
cytometry in blood samples to which 5- (and -6)-dichlorodihydrofluo­
rescein diacetate (DCFDA; catalogue No. C400; Molecular Probes), 
had been added. This non flu orescent dye is taken up by leukocytes and 
converted to a fluorescent derivative when exposed to ROIs in the 
cytoplasm. Controls included blood without added DCFDA or labeled 
bacteria and blood preincubated with DCFDA, but no bacteria. After 
these treatments, PE-conjugated anti-CD 14 was added to identify spe­
cifically monocytes.
Neopterin assay. Plasma samples frozen at -70°C and not thawed 
previously were assayed for neopterin by the IMMUtest Neopterin radio­
immunoassay kit (DRG International, Inc., Mountainside, NJ) using
0.05 ml of plasma rather than 0.02 ml for increased sensitivity.
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Measurement of complement components and immune complexes in 
plasma. Soluble immune complexes were measured by ELISA designed 
to replace the classic C lq binding and Raji cell assays (Quidel, San 
Diego, CA). The surrogate Clq binding test measures the quantity of 
IgG that is associated with Clq when captured by specific anti-Clq 
antibodies bound to microtiter plates. The surrogate Raji cell assay 
measures IgG associated with iC3b, C3d, and C3g when these fragments 
are captured in microtiter plates by anti-C3 antibodies. Total hemolytic 
complement (CH5o) was estimated by the method of Kent and Fife (21) 
as described in the Manual of Clinical Laboratory Immunology (22). 
Concentrations of complement fragments Bb and iC3b, indicative of 
activation of the alternative and the classic pathways, respectively, were 
assayed by ELISA (Quidel, Inc). As positive controls, we measured 
the quantity of Bb released in vitro alter zymosan activation and the 
quantity of iC3b released as a result of activation with aggregated IgG. 
Plasma, anticoagulated with EDTA and stored at —70°C, was thawed, 
recalcified, and immediately diluted 1:1 with zymosan, or with aggre­
gated IgG, to a final concentration of 1 mg/ml. An aliquot diluted 
1:1 with veronal-buffered saline provided a baseline reading. Treated 
samples were incubated in a shaking water bath at 37°C for 30 min. 
Reactions were stopped by placing the tubes on ice. Supernatants were 
separated by centrifugation at 15,000 g for 5 min at 4°C and then diluted 
between 1:50 and 1:200 in PBS containing 0.01% thimerosal and 0.05% 
Tween 20. 100-/il aliquots of these dilutions were dispensed in triplicate 
to wells of a 96-well microtiter plate that had been precoated with a 
mouse mAb to the relevant human complement fragment and then 
blocked with HSA to prevent nonspecific binding of plasma proteins. 
Bb or fragments of C3 were detected per the manufacturer’s instructions.
Treatment of leukocytes with soluble immune complexes or with 
leukocyte subcellular particles. Fc OxyBURST (Molecular Probes), an 
antigen-antibody complex created by allowing rabbit antibodies to BSA 
to react at equivalence with BSA covalently labeled with dichlorodihy- 
drofluorescein, was added at a concentration of 2 /¿g of complex per 
100 ¿¿1 of heparinized whole blood, a concentration chosen to activate 
ROI production maximally. Phagocytosis and internalization of the Fc 
OxyBURST by leukocytes results in oxidation of the colorless dichloro- 
dihydrofluorescein to the fluorescent dichloroiluorescein, just as 
DCFDA, previously described, becomes fluorescent when oxidized.
Subcellular particulates were obtained from co-cultures of MNLs 
from three unrelated donors, cultured together in the absence of detect­
able endotoxin (Limulus amebocyte assay) for 3-8 d in Iscove’s me­
dium supplemented with L-glutamine (Gibco Laboratories) and 10% 
FBS (Hyclone, Logan, UT). The 500-g cell-free supernatants of these 
cultures were centrifuged at 15,000 g for 15 min. The pellets obtained 
were washed, resuspended in fresh Iscove’s medium containing 10% 
FCS, and immediately added to whole blood as described in Results.
Endothelial adherence and transmigration. Assays were performed 
as previously reported (15), using bovine aortic endothelial cells (ob­
tained from Dr. Karen Frasier-Scott, University of Houston, Clear Lake, 
TX) cultured on 3-mm-thick pads of 50% collagen (Vitrogen, Celtrix, 
Palo Alto, CA). MNLs (0.5 X  10s) were added to the apical surface 
of unstimulated endothelium and to endothelial monolayers previously 
stimulated for 16 h with 10 ng/ml E. coli LPS. Nonadherent leukocytes 
were removed after a 2-h incubation at 37°C by gently washing the 
monolayer four times with warm medium. By adding 0.5 ml of IX 
trypsin for 4 min at 37°C and washing the monolayer two times, we 
then stripped off any leukocytes that adhered to the apical surface of 
the endothelium. Leukocytes that were still associated with the endothe­
lium after this treatment and those that had migrated into the collagen 
were recovered by digesting the trypsin-resistant collagen pad with 0.1% 
collagenase (Sigma Chemical Co.). MNLs recovered with the dissolved 
collagen were incubated with specific fluorochrome-conjugated mAbs 
and enumerated by flow cytometry. LeucoGATE (Becton Dickinson) 
a mixture of FITC-anti-CD45 and PE-anti-CD14, was used to discrimi­
nate monocytes from lymphocytes. MNLs had to be identified positively 
with a labeled mAb to distinguish them from the endothelial cells that 
remained in the trypsin-resistant fraction after collagenase digestion.
Statistics. Descriptive statistics included the arithmetic mean and
standard deviation. Because many variables were not normally distrib­
uted, a nonparametric method (Kruskal-Wallis one-way ANOVA cor­
rected for ties) was used to assess some group differences. Pairwise 
comparisons were done using Scheffe’s test with a significance level of 
5%. Analyses were conducted on SPSS (SPSS, Inc., Chicago, IL).
Results
Distinctive phenotypic characteristics of monocytes from stage 
A as compared with stage B/C HIV-infected patients, Counts 
of CD3 + T cells were significantly increased in stage A patients’ 
samples, both when compared with the numbers found in con­
trols, and in stage B/C patients’ blood; in the latter, the numbers
k
of CD3+ T cells were greatly reduced, approximating those 
seen in controls (Table I). CD8+ TCR al{3+ cells were largely 
responsible for the increased numbers of T cells in the stage A 
patients. The numbers of TCRy/ó4" T cells were decreased in 
stage B/C patients. CD19 + B cells appeared to be more abun­
dant in the early and CD56+ natural killer (NK) cells least 
abundant in the late stage patients, but these differences were 
not statistically significant. The numbers of CD1.4+ monocytes 
were somewhat reduced in all categories of patients, but there 
were no significant differences in the numbers of monocytes in 
blood samples from early and late stage patients (Table I). 
Plasma samples from 1 of 6 stage A patients contained HIV-1 
p24 antigen when tested both with and without acidification; 
10 of 19 stage B/C patients’ plasma contained p24, when tested 
without acidification; 2 additional stage B/C patients’ plasma 
samples revealed p24 antigen only when acidified, suggesting 
that in these two, all of the p24 antigen was incorporated in 
immune complexes (data not shown),
In the HIV-infected subjects, the percentage of monocytes 
expressing cell surface molecules that mediate adhesive interac­
tions with bacteria and endothelial cells was significantly al­
tered, but different abnormalities were seen in the early and 
late stage patients (Table II). For example, in the patients the 
percentage of monocytes expressing the L I6 activation epitope 
of CD II a/CD 18 was significantly increased, especially among 
stage A patients (Table II, A). The frequency of monocytes 
expressing HLA-DP and HLA-DQ was also significantly in­
creased in stage A patients, but in stage B/C patients, the fre­
quency of HLA-DR + and -DQ+ cells fell toward normal levels, 
Analysis of CD49d (VLA-4) expression by the nonparametric 
Kruskal-Wallis test suggested that there were significant differ­
ences in the percentages of positive monocytes in the patients 
and controls, the highest frequency appearing among cells of 
stage A patients. However, specific pairwise comparison of the 
frequency of VLA-4 among monocytes from patients and con­
trol donors did not reveal statistically significant differences, 
The percentage of monocytes expressing CD49e (VLA-5) 
and CD62L (L-selectin) as well as the abundance of these cell 
surface molecules, as estimated from MCF measurements, was 
significantly decreased in late stage patients (Table It, B and 
C). The frequencies of monocytes expressing CD29, CD 18, 
CDlla, CD54 (ICAM-1), CD58 (LFA-3), CD31 (PECAM-
1), and HLA-I also appeared to be significantly different among 
patients and the controls, as assessed by the nonparametric 
Kruskal-Wallis test (P < ,05; Table II B ). But with the excep­
tion of CD31, specific pairwise comparisons of the frequency 
of these antigens in the two patient groups or between either 
patient group and the controls showed no significant differences 
(see Table II B and Methods).
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Table I. Peripheral Blood Values in Controls and HIV-1* Patients with Early and Late Stage Disease
Parameters Controls Stage A Stage B/C P value A vs C B/C vs C A vs E
T cells 1,042±204 (8) 1,696±516 (6) 651 ±419 (18) <0.01 * NS *
CD4+ T cells 708±249 (8) 642±291 (6) 89±81 (19) ^  0.0001 NS * *
CD8+ T cells 389±121 (8) 913±206 (6) 655±357 (18) ^  0.0001 * NS NS
CD4/CD8 ratio 2.0±1.3 (9) 0.7±.2 (6) 0.1 ± .1 (19) 0.0001 * * NS
TCR a lp  T cells 95l±192 (8) 1,742±596 (4) 561±397 (15) ^  0.005 * NS %
TCG y/ô+ T cells 91±86 (8) 94±45 (3) 39±21 (15) sO.01 NS NS *
B cells 137±75 (8) 222±151 (5) 83±59 (19) NS NS NS NS
NK cells 206±114 (8) 182 ± 147 (4) 114 ± 167 (19) NS NS NS NS
Monocytes 768+400 (8) 399±336 (6) 381 ±447 (19) ^  0.05 NS NS NS
Patients were grouped by CDC classification into stage A (early disease) and stage B/C (late disease). Results are the numbers of peripheral blood 
cells in each subset based on the total white blood cell count (determined by Coulter counter), differential counts from stained blood smears, and, 
when applicable, immunofluorescence with specific mAbs. Total T cells were defined by the CD3 marker, B cells by CD 19, NK cells by CD57, 
and TCD alp and y 16 T cell subsets by specific mAbs. Values presented are the mean±SD for the total number of cells per mm3, excepting the 
CD4/CD8 ratio, which is calculated from the total CD4 and CDS counts for each individual. The number of subjects for each determination is 
indicated in parentheses. The P value represents the probability, estimated by the Kruskal-Wallis test, that the means could differ by the observed 
amounts if all groups were sampled from populations with identical means and standard deviations. The last three columns are pairwise comparisons 
of stage A versus controls (A vs C), stage B/C versus controls (B/C vs C), and stage A versus stage B/C (A vs B/C) using Scheffe’s test. Because 
Scheffe’s test assumes normally distributed data, it may not provide as powerful an estimate of statistical significance as the Kruskal-Wallis test.
* Significance at the 5% level. NS, not significant.
There were no significant differences in the frequency of 
monocytes expressing CD 1 lb/CD 18 (CR3) and CD 11 c/CD 18 
(CR4) in the blood from patients and controls, but these inte- 
grins were significantly more abundant, as estimated from MCF 
measurements, on the surfaces of monocytes from HIV-infected 
subjects, especially the stage B/C patients (Table II D). The 
percentage of monocytes expressing FcyRIII was slightly in­
creased in early (23.7±21.2%) as compared with late 
(16.5±14.3%) stage patients or controls (9.3±11.1%), but 
these differences were not statistically significant. Similarly, 
there were no significant differences in the percentage of mono­
cytes expressing FcyRI or FcyRII (data not shown).
Serial studies showed some variation in monocyte cell sur­
face expression of L I6, VLA-4, and L-selectin in selected pa­
tients (Fig. 1); but in general, values that were initially outside 
the normal range remained so over the 10±2 mo between mea­
surements.
The selectivity of these alterations in monocyte cell surface 
antigen expression was documented by the fact that the percent­
ages of cells expressing CDs 4, 15, 34, 35, 36, 41, 44, 45, 49b, 
61, and HLA-DR and the average abundance of these molecules 
on the monocyte surface as estimated by MCF were not signifi­
cantly different among patients and controls (data not shown, 
but available in appendices archived with the editors).
Monocyte phagocytic activity, production of ROIs, and 
transendothelial migration. Previously, we had observed that 
the fraction of monocytes in the blood of stage A patients that 
can phagocytose bacteria and produce ROIs is undiminished 
or, in some cases, significantly increased as compared with 
monocytes from uninfected controls (3). Using the same re­
agents and flow cytometric methods to study blood from stage 
B/C patients, we found that the fraction of monocytes that 
ingest Texas Red-stained S. aureus was significantly decreased. 
Specifically 59± 13% of monocytes from patients were effective 
phagocytes versus 72±10% of those from controls (P = 0.03, 
t test). However, 67±21% of the stage B/C patients’ phagocytic 
monocytes as compared with 68 ±14% of control donors’
phagocytic monocytes produced ROIs, and the quantities of 
DCFDA converted to a fluorescent oxidation product were simi­
lar in the phagocytes of patients and control donors: The MCF 
for oxidized DCFDA in the cells of stage B/C patients was 
89±5 as compared with 90±14 for the controls. Thus, although 
the fraction of monocytes able to phagocytose bacteria was 
reduced in stage B/C patients, the phagocytes that preserved 
this function retained a normal capacity to generate ROIs.
Production of ROIs was demonstrated in monocytes from 
55% of the stage B/C patients immediately after addition of 
DCFDA to the freshly drawn heparinized whole blood, sug­
gesting that these monocytes had been activated while still resi­
dent in the patients’ circulation. Spontaneous release of ROIs, 
detectable immediately after addition of DCFDA, was measured 
in <  15% of control donor monocytes in two sets of experi­
ments (see Fig. 2 and Table VI). The percentage of blood 
monocytes that spontaneously released ROIs correlated in­
versely with the fraction that ingested the Texas Red-labe led 
bacteria (Fig. 2), suggesting that the stimuli that induced intra- 
cytoplasmic release of reactive oxygen might also have been 
responsible for the diminished phagocytic capacity of the stage 
B/C patients’ monocytes.
Correlations between cell surface phenotype and phagocytic 
function. Phagocytosis of S. aureus correlated directly with 
monocyte cell surface expression of CD49e (VLA-5) (Fig. 3 C) 
and reciprocally with cell surface expression of CR3 (CD1 lb/ 
CD 18) (Fig. 3 A) and CR4 (CDllc/CDlS) (Fig. 3 B). Expres­
sion of the L16 activation epitope of LFA-1, however, bore no 
relationship to the capacity of these cells to phagocytose bacteria 
(data not shown).
Further evidence that the monocytes and/or the fixed tissue 
macrophages of late stage patients may be activated in vivo 
came from measurement of plasma neopterin levels. We found 
22.8± 10.5 nM/liter neopterin in the plasma of the late stage 
patients (stage B/C) as compared with 6.7±1.8 nM/liter in 
plasma of stage A patients and 4.7±2.4 nM/liter in plasma 
from normal controls (P < .001).
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Table 12. Phenotype Changes in Peripheral Blood Monocytes from Patients and Controls
B.
Antigen CD# Controls Stage A Stages B and C P value A vs C B/C vs C A vs B/C
Percentage of monocytes expressing antigens that
-
are most altered in stage A
Ll6 11a* 9±8 5 8 ±24 37+27 <  0.001
% % NS
HLA-DP 25±6 61±13 37 ±19 s  0.005 * NS
X
HLA-DQ 11 ±7 42+19 16+11 ^  0.05
t NS %
VLA-4 49d 52±11 66±12 44+23 0,05 NS NS NS
Percentage of monocytes expressing antigens that 
are most altered in stages B and C
ß l 29 95±3 93±4 88+8 <0.05 NS NS NS
VLA-5 49e 93 ±4 81±9 7 6 ± 15 ^  0.001 NS
t NS
ß2 18 95±5 91 ±8 86±11 0.05 NS NS NS
LFA-l 11a 95+3 93±4 89+8 <  0.05 NS NS NS
L-Selectin 62L 92±3 85±8 77±10 ^  0.001 NS
t NS
ICAM-1 54 94±4 92±5 79+22 ^  0.005 NS NS NS
LFA-3 58 89+11 84±12 74+21 ^0.05 NS NS NS
PEC AM-1 31 96+2 93 ±4 90+7 0.005 NS t NS
HLA-I 95±3 93 ±2 86± 14 ^  0.005 NS NS NS
MCF of monocytes positive for antigens changed 
most markedly in stages B and C
VLA-5 49e 121±7 116±23 103 ±9
1—
*
Oo
p
©VI NS * NS
L-Selectin
MCF of monocytes positive for antigens changed
62L 140+9 134+10 125±18 ^  0.05 NS * NS
in all stages of HIV-infected patients
MAC-1 l i b 116±U 131 + 16 130+14 sO.05 NS t NS
p i 50,95 lie 103+13 112±11 114+8 <  0.05 NS % NS
Peripheral blood MNLs were stained for surface antigens as described in Methods. Results presented are either the percentage of CD14+ monocytes 
positive for the noted marker (A and B) or the MCF of the positive cells (C and D), Data presented are the mean±SD. Statistical analyses of data: 
The P value shown in column 6 reflects the probability, measured by the Kruskal-Waiiis test, that the means for the controls, and the stage A 
versus stage B/C patients could differ by the observed amounts if all groups belonged to a population with identical means and standard deviations, 
The last three columns show pairwise comparisons of stage A versus control data (A vj C), stage B/C versus control data (B/C vs C), and stage A 
versus stage B/C (A vs B/C) using Scheffe's test. Because Scheffe’s test assumes normally distributed data, it may not provide as powerful an 
estimate of statistical significance as the Kruskal-Wallis test. * Activation epitope of CD 11 a. * Significance at the 5% level. NS, not significant.
Spontaneous trans endothelial migration of monocytes is de­
creased in the late stages of HIV-1 infection. Previously, we 
had shown that the ability of monocytes from stage A patients 
to migrate across confluent endothelial monolayers was unim­
paired (15). By contrast, the fraction of stage B/C patients’ 
monocytes that migrated, under standardized conditions» across 
both unstimulated and LPS-stimulated endothelium was sig­
nificantly reduced when compared with monocytes from stage 
A patients and with monocytes from normal controls (Fig. 4).
Immune complexes as likely stimulators for monocyte acti­
vation in the late stages of HIV infection. To evaluate whether 
immune complexes might induce certain of the phenotypic 
changes observed in the patients’ MNLs, we analyzed their cell 
surfaces for bound IgG. Regardless of CDC stage, 68.9±29.4% 
of all HIV-infected patients’ CD4+ T cells,'as compared with 
11.3+6.9% of normal donors’ CD4 + T cells, were coated with 
human IgG (P <  0.001). Similarly, 63.2+36.4% of patients’ 
as compared with 34.8+19.9% of the normal donors* CD8+ T 
cells (P <  0.05) displayed IgG. These results suggested either 
that antigens on the T cell surface may have bound anti-lympho- 
cyte antibodies or that immune complexes, scavenged from the 
plasma, might have bound to these cells’ Fc and/or complement
receptors. While the percentages of patients’ and control donors’ 
monocytes displaying cell surface IgG were not different, we 
found in 75% of the patients that the monocytes had gpl20 on 
their surfaces. The gp 120-specific mAb (1536) used in these 
studies cannot bind to gpl20 that is already complexed with 
CD4 (20). Thus the gpl20 found on patients' monocytes is 
likely to be gpl20 incorporated in antigen-antibody complexes 
that have associated with Fc receptors on the monocyte surface,
In the patients’ plasma samples, we found Clq-IgG im­
mune complexes to be especially abundant in stage B/C as 
compared with stage A patients and normal control plasma; 
however, C3~IgG complexes were only marginally increased 
(Table III).
Total hemolytic complement and C3 degradation products. 
Total hemolytic complement levels as estimated from the CH5n 
as well as the measurement of C3 degradation products, by
means of the ELISA for C3bi, suggested that turnover of circu-
i
lating complement was abnormally high in both early (stage 
A) and late (stage B/C) patients. This impression was rein­
forced by measuring C3bi levels after adding aggregated IgG 
to convert all available C3 to C3bi. The results of the latter test 
suggest that reduced synthesis of complement cannot account
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Figure 1. Variation in the percentage of CD14* monocytes that display 
the L I6 activation epitope of LFA-1, CD62L (L-selectin), and CD49d 
(VLA-4) markers over time. Each line represents the values from a 
single individual at the time of enrollment in the study (test 1) and at 
the second sampling (test 2), which occurred ~ 10 mo later (Í0±2 
mo). The shaded areas represent the normal range (mean ± 1 SD) for 
each monocyte marker from a group of 10 controls.
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Figure 2. Comparison of the phagocytic ability of stage B/C patients’ 
blood monocytes and their propensity to generate ROIs immediately 
upon removal from the circulation. Paired samples of leukocytes in 
whole blood were loaded with DCFDA and incubated in the presence 
or the absence of Texas Red-labeled S, aureus to measure their ability 
to generate ROIs with and without the stimulus provided by phagocyto­
sis of the bacteria. The percentage of CD14+ monocytes that generated 
ROIs without stimulation was plotted against the percentage of mono­
cytes that phagocytosed S. aureus. The assessment of the relation be­
tween these measurements gave an r value of -0.72 (P <  0.02). The 
mean of measurements from 10 control donors is represented by an X. 
The mean±l SD for the unstimulated oxidative burst was 5.05±4 for 
controls and 20.39±24 for the patients.
for the low CH50 values found in the patients’ plasma. Rather, 
these low values may be indicative of accelerated complement 
catabolism, a process that was, if anything, more active in the 
asymptomatic stage A patients, as suggested by their plasma 
C3bi levels (Table III).
Effects of immune complexes on monocyte phagocytic activ­
ity. Heparinized whole blood samples from healthy normal do­
nors were stimulated with Fc OxyBURST; this stimulation in­
duced the phenotypic and functional abnormalities seen in circu­
lating monocytes of late stage HIV-infected patients (Table 
IV ). After addition of these immune complexes, >  80% of the 
monocytes produced reactive oxygen. There was a concomitant 
reduction in their ability to phagocytose bacteria and a signifi­
cant increase in cell surface expression of CD1 lb and CD 11c, 
together with a >  50% reduction in the number expressing l -  
selectin and a 38% reduction in the number expressing VLA-5 
(Table IV). However, there was no significant change in the 
percentage of cells expressing the L I6 activation epitope of 
LFA-1. Stimulation of blood monocytes previously loaded with 
DCFDA with heat-aggregated human IgG, as an alternative 
surrogate immune complex, essentially duplicated the results 
shown in Table IV.
Effect of incubating monocytes with subcellular particles 
from apoptotic leukocytes. We postulated that, in HIV-infected
individuals, release of subcellular debris from leukocytes under­
going apoptosis might stimulate phenotypic changes observed 
in circulating monocytes, early in the course of HIV infection. 
To test this hypothesis, we exposed heparinized normal donor 
blood samples to subcellular particles, harvested at 15,000 g, 
from the supernatant« of mixed leukocyte cultures. Ultrastruc- 
tural studies of phagosomes of monocytes obtained from blood 
that had been exposed to these subcellular particles (Fig. 5) 
showed that they contained nuclei with condensed chromatin, 
swollen but intact mitochondria, and sealed vesicles, consistent 
with the notion that the subcellular particles had been ingested 
by these phagocytes.
Incubation with the subcellular particles for 90 min at 37°C 
stimulated expression of L I6 in nearly 40% of normal donor 
monocytes. However, incubation with freshly isolated intact 
allogeneic or autologous mononuclear cells or with freshly iso­
lated mononuclear cells that had been killed by pulsed ultra­
sound, repeated cycles of freezing and thawing, or heat (2 h at 
42°C) had no effect on monocyte L16 expression, even when 
the stimulatory cells were opsonized with mAbs specific for 
HLA-DR or CD3 (Table V ) .
In addition to stimulating cell surface expression of L I6, 
the subcellular particulates induced other monocyte phenotypic
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Figure 3. Correlation of surface markers with the ability of patients’ 
monocytes to phagocytose Texas Red-labeled S. aureus. Leukocytes 
in blood were incubated with bacteria at a 10:1 bacteria/leukocyte ratio
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Figure 4. A significantly 
smaller percentage of 
monocytes from stage B/ 
C patients as compared 
with monocytes from 
normal controls migrate 
across confluent endo­
thelial monolayers (P 
<  0.03, t test). Migra­
tion of patients’ mono­
cytes was defective across both unstimulated endothelium (striped bars) 
and LPS-stimulated endothelium (stippled bars).
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changes seen in HIV-infected patients (Table VI). These in­
cluded increased cell surface expression of CD lib  and CD 11c 
and a decrease in the percentage of cells expressing L-selectin. 
There was also a slight decrease in the percentage of cells 
expressing VLA-5, but the change in cell surface VLA-5 was 
considerably less than that seen after stimulation with immune 
complexes (compare data in Tables IV and VI). In addition, 
stimulation with either LPS or subcellular particles induced 
about a threefold increase in the numbers of cells that released 
ROIs intracellularly (Table VI). This suggested that the oxida­
tive burst might have been stimulated by phagocytosis of these 
particles.
Opposing effects of stimulation with immune complexes and 
subcellular debris upon the ability of mononuclear cells to mi­
grate across endothelial monolayers. Incubation with subcellu­
lar debris under conditions that induced monocyte cell surface 
expression of L I6 and other phenotypic changes documented in 
Table VI enhanced the capacity of blood monocytes to traverse a 
monolayer of human umbilical vein endothelial cells, whereas 
stimulation with immune complexes under conditions that re­
duced monocyte phagocytic activity and decreased expression 
of L-selectin and VLA-5, as shown in Table IV, impaired this 
behavior (Table VII).
Effects of bacterial products on monocyte cell surface phe­
notype and function. Stimulation of heparinized whole blood 
with LPS induced phenotypic and functional changes in mono­
cytes that were intermediate between those caused by immune 
complexes and those caused by subcellular particulates from 
apoptotic lymphocytes. Addition of LPS caused a dose-depen­
dent increase in the percentage of monocytes expressing the 
L I6 activation epitope of LFA-1; maximum expression of L16 
occurred after 90 min of incubation at doses >: 1 /¿g/ml (Fig. 
6). However, the ability of cells stimulated with LPS to migrate
for 100 min. Other blood samples were processed for immunofluores­
cence as described in Methods. The percentage of CD14+ monocytes 
ingesting bacteria was plotted against the MCF of CD lib  (A, n = 9), 
the MCF of CD1 lc (£, n = 10), and the MCF of VLA-5 ( C, n = 10). 
Lines represent regression curves for patient values in each plot, and 
the appropriate r values are -0.95 for A (P <  0.0001 ), -0.86 for B 
(P <  0.001), and 0.65 for C (P <  0.05). The means of values from 
10 control individuals are represented by the X in each panel. M eanil 
SD for the percentage of phagocytic cells was 72±14 for controls and 
58±4 for patients; for C D llb  these MCF values were 140±10 for 
controls and 153±8 for patients; for CDllc these MCF values were 
105±3 for controls and 112±3 for patients; and VLA-5 MCF these 
values were 131 ±2 for controls and 127±2 for patients.
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Table III. Immune Complex Levels, CH50 » and Complement 
Degradation Products
Assay Controls Stage A P value* Stage BfC P value*
CIC-Clq Owg/ml)§ 1 ±2 3±2 0.009 , 6±5 0,0002
CIC-C3 frag (/¿g/ml)1 8±10 13± 10 NS 151:11 NS
CHm (U)* 57±19 31±20 0.01 32 ±22 0.0009
iC3b (//g/ml)** 6 ±7 17±13 0.02 12±13 NS
iC3b act. (//g/ml)** 407±106 469±183 NS 379±108 NS
Plasma samples from 15 controls, 6 early (stage A) disease, and 19 late (stage 
B/C) disease were tested. Data are presented as the mean±SD, * Probability that 
the stage A patients differed from the control group (unpaired Student’s / test).
* Probability that the stage B/C patients differed from the control group (unpaired 
Student’s t test). 5 Circulating immune complexes measured as IgG bound to 
Clq. Circulating immune complexes measured as IgG complexed with C3,
1 Total complement activity. ** Basal levels of C3bi by ELISA. n  Levels of 
C3bi measured by ELISA after in vitro addition of aggregated IgG to recalcified 
plasma. NS, not significant.
across endothelial monolayers was significantly reduced (data 
not shown).
To investigate whether exposure to whole bacteria caused 
similar phenotypic changes, blood samples were incubated with 
E. coli,  S. pneumoniae, or S. aureus. Each of these had been 
labeled with Texas Red. After phagocytosis of E. coli, 46% 
of monocytes expressed the L16 epitope of LFA-1, whereas 
exposure to S. pneumoniae caused 11 % of monocytes to express 
this activation epitope. Stimulation with S. aureus, a  1 mg/ 
ml zymosan, or a  10 ptM f-MLP caused no increase in L16 
expression above baseline.
Effect of proinflammatory cytokines and viral products on 
monocyte cell suiface phenotype. Considering that diverse pro- 
inflammatory cytokines and viral gene products may be released 
into the circulation of infected subjects, we investigated the
Table IV. Effect o f Immune Complexes on Monocyte Phagocytosis 
and Expression of Surface Molecules
Parameter No treatment Immune complexes P value*
Phagocytosis (% pos.)^ 51 + 11 6±3 0.005
CD 11 b (MCF)§ 111 ± 10 147±27 0.02
CD lie  (MCF) 94±15 109 ±12 0.02
L16 (% pos.) 11 it 14 15±5 NS
L-Selectin (% pos.) 67±13 12±4 0.01
VLA-5 (% pos.) 71±21 33 ±20 0.02
Cells taking up IC1 NA 83±4
Samples of peripheral blood (100 ¡A) from normal donors were incu­
bated for 1 h at 37°C with immune complexes (2 fig of Fc OxyBURST 
in 2 (A) or 2 ¡A of buffer (No treatment). To measure phagocytosis, 
Texas Red-labeled S. aureus was added to some samples at a 10:1 
bacterial/leukocyte ratio for 100 min. Other aliquots of blood were 
chilled to 4°C and stained with mAbs against the indicated surface 
markers (CDllb, CD1 le, L16, L-selectin, and VLA-5) followed by PE- 
conjugated goat anti-mouse Ig. Data are the mean±SD for four control 
donors for phagocytosis and three donors for surface markers. * Sig­
nificance by Student’s t test for paired samples. * Percentage of all 
monocytes positive for marker. § MCF of positive monocytes based on 
a 256-channel histogram. 1 Percentage of cells producing reactive oxy­
gen products after uptake of the Fc OxyBURST. IC, immune complexes. 
NA, not applicable. NS, not significant.
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Figure 5. Electron micrograph of monocytes exposed to subcellular 
particles. A cell preparation enriched for monocytes (2 X 106) was 
incubated with the 15,000-# sediment from the 500-# culture superna­
tant of 16 X 106 mononuclear cells that had been involved in a three- 
way mixed leukocyte reaction for 7 d. After a 2-h incubation, the mono­
cytes were fixed in glutaraldehyde and processed for electron micros­
copy. Apoptotic bodies in phagosomes are marked by single arrows and 
apoptotic bodies still external to the cells are marked by double arrows. 
N, nucleus. X 15,000 Bar, 1 /¿m.
possibility that specific cytokines or proteins encoded by the 
virus could stimulate the expression of the LI 6 activation epi­
tope of LFA-1 and other phenotypic changes that we saw in 
monocytes of HIV-infected subjects. Addition of between 1 and
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Table V. Induction of the L I6 Epitope on Normal Donor 
Monocytes after Incubation with Siibcellular Particles 
but Not after Stimulation with Intact MNLs
Stimulus Percentage o f monocytes expressing L t6
0.5 X  IO6 intact MNLs 1±9
1.0 X  IO6 intact MNLs 2±2
2.5 X  IO6 intact MNLs 2± 1
5.0 X  10" intact MNLs 3±2
Subcellular particles 56±1
Whole blood (1 ml) was treated for 90 min with varying doses of viable 
leukocytes ranging from 0.5 X 106 to 5.0 X 106 or with subcellular 
particles from ihe culture supernatant of 5 X 106 MNLs stained to 
identify cells expressing the L I6 epitope, and analyzed by flow cytome­
try, The stimulating leukocytes were 95-97% viable and 15-23% 
CD14+. Results presented are the difference in the numbers of CD 14* 
monocytes expressing L16 in treated and untreated samples. The base­
line expression of L I6 in untreated blood was 12±3%. Values listed 
are the mean±SD of the results obtained with three donors.
10 ng/ml recombinant human TNF-a, IFN-7 , IL-4, TGF-¡3, 
PDGF, GM-CSF, and platelet-activating factor to blood from 
normal donors significantly reduced the percentage of mono­
cytes that expressed L-selectin without affecting the percentage 
that expressed LI 6, For example, L-selectin was found on 
87±6% of unstimulated monocytes and decreased to an average 
of 70±13% after exposure to 1 ng/ml TNF-o: and to 52±20% 
after exposure to 10 ng/ml TNF-o?, whereas the fraction of 
monocytes expressing L I6 was 7±4% in untreated blood and 
remained at 9±2% for all doses of TNF-a. Treatment with IL- 
1 a or IL-1/3 within the same dose range had no effect on either 
L-selectin or L16 expression. Similar decreases in L-selectin 
expression were observed after incubation with up to 5 /ig/ml
► ___
Table VI. Effect o f LPS and Subcellular Particles on Monocyte 
Phagocytic Activity and Cell Surface Expression of CD lib , 
CDUc, L I6, cincl CD62L
Parameter No treatment LPS P value* SCP P value*
Phagocytosis (% pos.)§ 75± 14 79± 14 NS 75±13 NS
CD! lb (MCF)1 159±i 1 181 + 7 0,006 165±11 0.002
C D llc  (MCF) 121 + 15 114±7 0.01 138+5 0.02
L I6 (% pos.) 23± 14 71 + 18 0.0002 67 ±20 0.00002
CD62L (% pos.) 81 ± 13 21 + 18 0.001 62+3 0.01
VLA-5 (% pos.) 92±21 92±2 NS 91± 1 0.02
Oxidative burst (% pos.) 15+9 39 ±23 0.007 44 ±26 0.005
Samples of peripheral blood (100 ¿¿1) from normal donors were incubated For 90 
min at 37°C with 1 /£g/ml LPS or the subcellular particles {SCP) harvested from 
4 X 10fl MNLs in a 5-cl three-way mixed leukocyte reaction. Some aliquots were 
then incubated with Texas Red-labeled S, aureus to measure phagocytosis; others 
were chilled to 4°C and stained with mAbs to C D llb , C D llc , L16, L-selectin, 
or VLA-5, followed by FITC-conjugated anti-mouse mAb. To measure oxidative 
burst* cells were preloaded with DCFDA before exposure to subcellular particles 
or LPS. All samples were counterstained with PE-conjugated anti-CD 14 to iden­
tify monocytes. Data are the mean±SD for five donors for surface markers and 
eight donors for the remaining studies. * The probability that LPS treatment 
differs from no treatment; Student’s t test for paired samples. * The probability 
that subcellular particles treatment differs from no treatment; Student’s t test for 
paiied samples. 5 Percentage of CD14+ monocytes positive for marker. " MCF 
of positive monocytes based on a 256-channel histogram,
NS, not signiiicant.
Table VII. Effect o f Immune Complexes and Subcellular Particles 
on Monocyte Transendothelial Migration
Treatment Numbers of migrating monocytes P value*
Medium 2,560±300
Subcellular particles 3,500±100 0.006
Fc OxyBURST 400±60 0.001
Equal numbers of normal donor MNLs were incubated with medium, 
subcellular particles, or Fc OxyBURST for 1 h at 37°C and then allowed 
to migrate through confluent monolayers of bovine aortic endothelial 
cells for 2 h. PE-conjugated anti-CD 14 was used to identify the mono­
cytes among the MNLs that migrated through the endothelium to facili­
tate their enumeration by flow cytometry. The table shows the mean±SD 
for triplicate determinations. * Statistical analysis (t test) comparing 
results of samples treated with subcellular particles or Fc OxyBURST 
and those treated with tissue culture medium.
recombinant gpl2Q or gpl60, produced in baculovirus-infected 
cells, or stimulation with the same quantities of recombinant 
rev or reverse transcriptase, produced in E. coli, but none of 
these agents induced L16 expression (data not shown). Treat­
ment with 1-30 recombinant tat and 10 (ig/ml recom­
binant p24 also had no effect on monocyte L16 expression (data 
not shown).
Discussion
The results of the present studies are consistent with the notion 
that capture of antigen-antibody complexes by lymphoid tis­
sues decreases significantly during the course of HIV infection 
(1, 2, 13, 23-25). Excessive numbers of IgG-coated T cells 
and gpl20-coated monocytes were found at all stages of HIV 
infection, but high levels of IgG-Clq immune complexes were 
especially abundant in the late stage patients. Considered to- 
gether with data suggesting that intravascular complement acti­
vation proceeds at a brisk pace even in stage A patients, these 
results support the idea that lymphoreticular clearance of im­
mune complexes becomes less effective in the late stages of 
infection (13). This conclusion is also consistent with data
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Figure 6. Kinetics of the 
monocyte response to 
stimulation with E. coli 
LPS. Whole blood was 
treated for the indicated 
times with PBS (lower 
line) or with 1 /¿g/ml 
LPS (upper line), and 
the CD14+ cells were as­
sessed for display of the 
LI 6 epitope of LFA-1. 
The points represent the 
mean ±SEM of data from 
three different donors.
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showing that sequestration of large quantities of virus, com- 
plexed with antibody and complement, in germinal centers is a 
prominent feature early in HIV-1 infection (2). The disorgani­
zation of follicular architecture and decline in numbers of folli­
cles that contain virus-antibody complexes in the late stages 
of infection (2, 24, 25) also suggest that the capacity of the 
lymphoreticular system to remove immune complexes declines 
as the disease progresses.
A particularly novel feature of this study is the demonstra­
tion that monocytes in advanced HIV infection display a distinc­
tive cell surface phenotype that may be representative of mono­
cytes that have been activated to release ROIs. These cells also 
appeal* to have reduced ability to migrate across endothelial 
monolayers and phagocytose bacteria. By stimulating normal 
donor monocytes with antigen-antibody complexes, formed at 
equivalence, or aggregated human IgG in vitro we were able 
to replicate phenotypic and functional abnormalities seen in 
these late stage patients’ monocytes.
Equally novel is the recognition that distinctive characteris­
tics of monocytes from stage A patients, including a normal or 
enhanced ability to phagocytose bacteria and migrate across 
endothelial monolayers (3, 15), could be replicated in vitro by 
exposing normal donor monocytes to subcellular particulates 
released as the result of apoptosis. The augmented phagocytic 
and antibacterial activities (3, 4) that result from stimulation 
with such subcellular particulates may offset, for a while, the 
defects in T cell-mediated immune function that begin to ac­
crue even in the early stages of HIV infection (2).
Our results suggest that at some critical juncture in HIV 
infection, a qualitative change occurs in the environment of 
circulating monocytes that modifies their ability to phagocytose 
bacteria and to emigrate into soft tissues. Consequently, their 
ability to orchestrate an appropriate host defense against infec­
tious agents declines (9-12). The data reported here are the 
first, to our knowledge, to provide evidence that monocytes of 
HIV-infected individuals ultimately develop functional defects 
reminiscent of those seen in leukocytes of patients with leuko­
cyte adhesion deficiency syndrome, in whom abnormal cell sur- 
face expression of key adhesion molecules significantly impairs 
leukocyte surveillance against soft tissue infection (26).
The present studies suggest that subcellular’ particulates re­
leased from apoptotic leukocytes can signal normal donor 
monocytes to express the phenotypic and functional properties 
of monocytes from stage A patients. Spontaneous apoptosis 
may be one of the agents responsible for loss of both infected 
and uninfected T cells in HIV-infected individuals (27, 28). 
Cross-linking of cell surface CD4 molecules by gpl20, or anti­
body plus gpl20 bound to CD4 (29, 30) as well as products 
of HIV-1-infected macrophages, such as prostaglandin E2 
(31), may induce apoptosis of uninfected autologous lympho­
cytes. Subcellular components released by apoptotic lympho­
cytes are thus likely to be abundant in lymphoid tissues (32) 
and peripheral blood (30) early in the course of HIV infection. 
Although cells of many lineages can ingest apoptotic cells and 
their subcellular vesicular debris, monocytes and tissue macro­
phages are particularly well adapted for this role (33). For 
example, macrophages can recognize and remove senescent 
neutrophils before they release their granular contents (33). 
Whereas mature monocyte-derived macrophages that phagocy­
tose apoptotic neutrophils or lymphocytes via vitronectin recep­
tors do not appear to be activated, as measured by release of 
thromboxane B2 or the granule enzyme N-acetyl-/3-d-g lucosam-
inidase (34), monocytes that phagocytose apoptotic neutrophils 
that have been opsonized with immune serum will be activated 
according to these criteria. Thus, whether or not macrophages 
become activated appears to depend on the type of receptor 
used to take up the particulates. In studies of freshly isolated 
blood monocytes, we have not been able to demonstrate 
vitronectin receptors by immunofluorescence using mAb 
against av (data not shown). Thus it is possible that freshly 
harvested blood monocytes respond differently from mature 
monocyte-derived macrophages, or that they use different re­
ceptors to phagocytose particulates from apoptotic leukocytes.
Recent studies demonstrating that neoplastic epithelial cells 
can take up plasma membrane-delimited vesicles shed by leu­
kocytes and subsequently display leukocyte proteins, formerly 
incorporated in those vesicles, on their cell surfaces (35) raise 
the possibility that some of the observed changes in monocyte 
surface protein expression may have resulted from uptake of 
vesicles from apoptotic leukocytes rather than an increase in 
endogenous synthesis of these molecules. CDlla/CD18 (LFA- 
1) was among the cell surface proteins passively transferred to 
epithelial cells by such a mechanism (35); as a result, the 
epithelial cells developed novel adhesive properties, specifically 
the ability to bind to ICAM-1-coated beads and to endothelial 
cells. ■
Although incubation of normal donor monocytes in vitro 
with E. coli LPS stimulated L16 expression, we found that LPS 
stimulation did not replicate all of the phenotypic and functional 
characteristics of monocytes from stage A patients. For exam­
ple, LPS stimulation did not reduce the frequency of cells ex­
pressing VLA-5, and it suppressed migration of normal donor 
monocytes across endothelial monolayers (data not shown). In 
stage A patients, spontaneous migration of monocytes across 
endothelial monolayers (15) was not decreased. Since there 
is little evidence that asymptomatic HIV-infected individuals 
experience frequent episodes of gram-negative bacteremia, we 
suggest that exposure to products of these bacteria in vivo is 
not likely to be responsible for the monocyte phenotypic 
changes seen in stage A patients.
In other studies, immune complexes have also been found 
on T cells, on monocytes (36), and in cell-free plasma of HIV- 
infected subjects (37, 38) at all stages of the infection (39). 
In addition, immune complexes have been implicated in the 
pathophysiology of the thrombocytopenic purpura seen in HIV- 
infected subjects (40), as agents that can cause CD4+ T cell 
unresponsiveness (41), and as a cause of IgA nephropathy in 
HIV-infected patients (42). It has been suggested that com­
plexes incorporating infectious HIV-1 and antibodies to viral 
gpl20 can be taken up by Fc receptors (43) and facilitate infec­
tion of monocyte-derived macrophages (44-46). It is not clear, 
however, that infection depends exclusively on Fc receptor- 
mediated uptake of virus-antibody complexes by these cells 
(47, 48). Exposure to circulating immune complexes may also 
suppress neutrophil bactericidal activity in AIDS patients (49) 
and, by saturating the available Fc receptors of fixed tissue 
phagocytes, may significantly reduce intravascular clearance of 
opsonized particulates (13, 50).
The comparatively low levels of IgG-Clq complexes in 
sera of stage A patients were evidently not sufficient to depress 
monocyte phagocytosis and ROI generation (3), possibly be­
cause the capacity of the mononuclear phagocyte system to 
clear circulating immune complexes had not yet been severely 
compromised. In our experiments (Table IV), addition of s: 20
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//g/ml Fc OxyBURST or heat-aggregated human IgG was 
needed to stimulate significant ROI production and to suppress 
monocyte phagocytosis of S. aureus. Thus both in vivo and in 
vitro, it would appear that a critical threshold concentration of 
immune complexes is needed to alter monocyte function.
Data in Fig. 3 C emphasize the importance of CD49e/CD29 
(VLA-5)-mediated interactions in monocyte phagocytosis of 
gram-positive bacteria. Reduction in both the cell surface ex­
pression and the percentage of monocytes expressing this fi- 
bronectin receptor may explain the reduced uptake of S. aureus 
in these experiments (51, 52). Signaling induced by uptake 
of immune complexes may modulate monocyte cell surface 
expression of VLA-5, since significant loss of VLA-5 in vitro 
and phagocytic activity (Table IV) followed within 1 h after 
stimulation with this reagent.
The data in Table II show distinct abnormalities in cell 
surface phenotype that discriminate monocytes from stage A as 
compared with stage B/C patients. Previous studies have not 
identified distinct abnormalities in monocyte cell surface anti­
gens in HIV-infected individuals (53). However, these earlier 
studies used a less extensive battery of mAb reagents and did 
not attempt to relate changes in monocyte antibacterial activity 
to changes in cell surface phenotype.
Monocytes isolated from normal donor blood by various 
methods, though functionally and phenotypically heteroge­
neous, are not strictly divisible into specific subpopulations; the 
functional and phenotypic diversity seen here and in other stud­
ies may reflect a continuum of maturational and activation states 
(54). Although we have stressed the differences seen in mono­
cytes of stage A versus stage B/C patients, we recognize, as 
the data in Table II illustrate, that the observed differences are 
not strictly dichotomous. Abnormalities such as the increased 
cell surface expression of CD IIb /CD lS  and CDllc/CD18 
were seen in all patients. Other abnormalities, such as the in­
creased frequency of cells expressing the LI 6 activation epitope 
of LFA-1, though seen predominantly in stage A patients’ 
monocytes, were also seen in some patients with advanced dis­
ease (Table II). Thus abnormalities seen predominantly in leu­
kocytes from one or another category of patients may reflect 
the diversity and heterogeneity of stimuli that affect monocytes 
of HIV-infected subjects during the prolonged course of this 
disease.
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